RT Journal Article
SR Electronic
T1 Modelling the Impact of Delaying Vaccination Against SARS-CoV-2 Assuming Unlimited Vaccines Supply
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.22.21252189
DO 10.1101/2021.02.22.21252189
A1 Marcos Amaku
A1 Dimas Tadeu Covas
A1 Francisco Antonio Bezerra Coutinho
A1 Raymundo Soares Azevedo
A1 Eduardo Massad
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252189.abstract
AB Background At the moment we have more than 109 million cases and 2.4 million deaths around the world and vaccination represents the only hope to control the pandemic. Imperfections in planning vaccine acquisition and difficulties in implementing distribution among the population, however, have hampered the control of the virus so far.Methods We propose a new mathematical model to estimate the impact of vaccination delay against COVID-19 on the number of cases and deaths by the disease in Brazil. We apply the model to Brazil as a whole and to the State of Sao Paulo, the most affected by COVID-19 in Brazil. We simulated the model for the populations of the State of Sao Paulo and Brazil as a whole, varying the scenarios related to vaccine efficacy and compliance from the populations.Results The model projects that, in the absence of vaccination, almost 170 thousand deaths and more than 350 thousand deaths until the end of 2021 for Sao Paulo and Brazil, respectively. If in contrast, Sao Paulo and Brazil had enough vaccine supply and so started a vaccination campaign in January with the maximum vaccination rate, compliance and efficacy, they could have averted more than 112 thousand deaths and 127 thousand deaths, respectively. In addition, that for each month of delay the number of deaths increases monotonically in a logarithm fashion, for both the State of Sao Paulo and Brazil as a whole.Conclusions Our model shows that the current delay in the vaccination schedules that is observed in many countries has serious consequences in terms of mortality by the disease and should serve as an alert to health authorities to speed the process up such that the highest number of people to be immunized is reached in the shortest period of time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by LIM01-HFMUSP, CNPq, FAPESP and Fundacao Butantan. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a theoretical model and no human volunteers has been recrutedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data can be requested to the author at the e-mail edmassad{at}dim.fm.usp.br https://www.seade.gov.br/coronavirus/#